Astria Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Astria Therapeutics

02/08/2024 13:43

* Astria Therapeutics Inc  ATXS.OQ   ATXS.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 5 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Astria Therapeutics Inc
is for
a loss of 38 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Astria
Therapeutics Inc is $25.00​, above​ its last closing price
of $11.19. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.37       -0.36      -0.38     Missed  -4.4
 Dec. 31 2024  -0.78       -0.78      -0.94     Missed  -20.5
 Jan. 1 0001               -0.49      -0.63     Missed  ​
 Jan. 1 0001                          -0.45             7.6
 ​​Jan.        -0.57       -0.55      -0.40     Beat    27.5
 1 0001                                                 
 Jan. 1 0001   -0.57       -0.71      -0.72     Missed  -1.2​
 Sep. 30 2022  -0.91                  -0.87             5.2
 Jun. 30 2022  -0.99       -1.01      -0.86     Beat    15.3
 This summary was machine generated August 2 at 12:43 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)